No Data
Dajia VICOM Ltd (301126.SZ): The application for issuing Stocks to specific targets has been accepted by the Shenzhen Stock Exchange.
On December 30, Gelonghui reported that Dajiao VICOM Ltd (301126.SZ) announced that it recently received the notice from the Shenzhen Stock Exchange regarding the acceptance of the application documents for the issuance of stocks to specific targets by Hunan Dajiao VICOM Ltd (Shenzhen Stock Exchange Review [2024] No. 319). The Exchange verified the application documents submitted by the company for the issuance of stocks to specific targets, concluded that the application documents are complete, and decided to accept it.
Dajiahui vicom ltd (301126.SZ) specific shareholder Liangji Investment and its concerted parties completed a shareholding of 1.7391 million shares.
Dajia Vicom Ltd (301126.SZ) announced that as of December 5, 2024, the specific shareholder Ningbo Meishan...
Dajia Weikang (301126.SZ) 81.8702 million shares of restricted shares will be listed and traded on December 9th.
Dajia Vicom Ltd (301126.SZ) announced that the number of shareholders whose restricted shares are released is a total of 5 households, and the restricted shares have been released...
Daga Weikang: Report for the third quarter of 2024
Vicom Ltd (301126.SZ): Its subsidiary, Jiachen Hospital, is actively promoting the application for human assisted reproduction license qualification.
Gelonghui October 11th | Dajia vicom ltd (301126.SZ) stated at an investor relations event that its subsidiary, Jiachen hospital, is actively pursuing the application for human assisted reproduction license qualification. Due to the high barriers of assisted reproduction technology, lengthy licensing application processes, and strict approval standards, there is uncertainty about the prospects of the company's continued assisted reproduction business.
Vicom Ltd (301126.SZ): invested 10 million yuan to establish a wholly-owned subsidiary Vicom Ltd Regenerative Medicine Research Institute.
On September 27, Gelonghui announced that in order to further meet the needs of its global strategy, enhance the company's market competitiveness, the company used its own funds to set up a wholly-owned subsidiary, Hunan Dajiaweikang Regenerative Medical Research Institute Co., Ltd. (hereinafter referred to as "Dajiaweikang Regenerative Medical Research Institute"). Recently, the Dajiaweikang Regenerative Medical Research Institute has completed the industrial and commercial registration and obtained the "Business License" issued by the Changsha County Market Supervision Administration. The establishment of this wholly-owned subsidiary will help further strengthen the company's development in the field of medical services and enhance the company's leading position in this area.
Investors Still Aren't Entirely Convinced By Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Revenues Despite 28% Price Jump
